Pharming Acquires Exclusive License to CDZ173, a Late Stage Drug for the Treatment of APDS


-- CDZ173 is in a registration-enabling study for the treatment of APDS, an ultra-rare, debilitating disease with no approved treatment -- APDS is treated by ... Lees verder

Bron: ANP Pers support
Tags:
Geplaatst: 13 aug 2019 - 07:01